Vimarsana
Biggest News Aggregation in the World

Michael Sheikh News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Michael Sheikh. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Michael Sheikh Today - Breaking & Trending Today

Bioxytran Announces Broad Spectrum Antiviral Activity - Vimarsana News

Bioxytran Announces Broad Spectrum Antiviral Activity

BOSTON, MASSACHUSETTS, Sept. 14, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral...

Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials - Vimarsana News

Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials

First Antiviral Drug in GlycovirologyBOSTON, MASSACHUSETTS, Aug. 24, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinica...

Bioxytran Initiates a Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID-19 Patients - Vimarsana News

Bioxytran Initiates a Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID-19 Patients

BOSTON, MASSACHUSETTS, Aug. 08, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the "Company"), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral diseases, announced the

IN8bio, Inc (NASDAQ: INAB): Our Biotech Focus Stock - Vimarsana News

IN8bio, Inc (NASDAQ: INAB): Our Biotech Focus Stock

IN8bio, Inc (NASDAQ: INAB) just released very enticing positive data from their phase 1 investigator-sponsored trial of INB-100 in Leukemia patients.

The Inside Scoop On Petros Pharmaceuticals (NASDAQ: PTPI) - Vimarsana News

The Inside Scoop On Petros Pharmaceuticals (NASDAQ: PTPI)

On Friday, Petros Pharmaceuticals (NASDAQ: PTPI) stock witnessed a significant uptick in value, despite the absence of any company updates regarding its men's health pharmaceutical products. There’s no evidence of any press release or filed reports with the U.S. Securities or Exchange Commission to explain the rise in value. To Find out the inside Scoop